Search

Your search keyword '"Shousha, Hend Ibrahim"' showing total 153 results
Start Over Author "Shousha, Hend Ibrahim"
153 results on '"Shousha, Hend Ibrahim"'

3. Climate Changes and COVID-19

Author

Shousha, Hend Ibrahim, Ayman, Hedy, Hashem, Mohamed B., Crusio, Wim E., Series Editor, Dong, Haidong, Series Editor, Radeke, Heinfried H., Series Editor, Rezaei, Nima, Series Editor, Steinlein, Ortrud, Series Editor, Xiao, Junjie, Series Editor, and Rosenhouse-Dantsker, Avia, Editorial Board Member

Published
2024
Full Text
View/download PDF

18. PD-L1 small molecule inhibitors and Paclitaxel orchestrating CD8+ cell cytotoxicity via tumor-associated macrophages: a personalized HCC immunotherapeutic approach

Author

Helal, Israa, primary, Kamal, Monica A., additional, Ramadan, Ahmed, additional, Elbaz, Tamer, additional, Nabeel, Mohamed Mahmoud, additional, Elfishawi, Sally, additional, Shousha, Hend Ibrahim, additional, Omar, Ashraf, additional, Mandour, Yasmine M., additional, and El Tayebi, Hend, additional

Published
2023
Full Text
View/download PDF

19. Anxiety, depression and coping strategies among chronic medical patients with coronavirus disease-2019: a multicenter follow-up cohort study.

Author

Shousha, Hend Ibrahim, Madbouly, Nagwan, Afify, Shimaa, Asem, Noha, Fouad, Eman, Maher, Rabab, Moussa, Suaad Sayed, Abdelazeem, Amr, Youssif, Eslam Mohamed, Harhira, Khalid Yousef, Kamal, Kariman, Elmorsy, Hazem, Elgarem, Hassan, Omran, Dalia, Hassany, Mohamed, Eysa, Basem, and El Kassas, Mohamed

Subjects
*MENTAL depression risk factors, *RESEARCH, *COVID-19, *SOCIAL support, *CHRONIC diseases, *RISK assessment, *SURVEYS, *QUESTIONNAIRES, *ANXIETY, *PSYCHOLOGICAL adaptation, *PSYCHOLOGY of the sick, *LONGITUDINAL method, *DISEASE complications
Abstract

Studies have shown that COVID-19 patients experience high levels of anxiety, depression, and stress during the pandemic. Patients adopt different coping strategies to reduce their psychological distress To compare the immediate and long-term psychological impact of COVID-19 disease on patients with and without chronic medical illnesses (CMI) and identify coping styles of both groups during the peak of COVID-19 disease in Egypt. This is a cohort follow-up study, that included an online survey consisting of General Health Questionnaire-12, Taylor Manifest Anxiety Scale, Beck Depression Inventory and Brief-COPE scale. The Post-Traumatic Stress Disorder (PTSD) Checklist was completed after 6 months. Questionnaires were distributed to adult patients with a confirmed diagnosis of SARS-CoV-2 virus infection during their quarantine in Egypt. There was no significant difference between the two groups regarding anxiety and depression during the acute infection. Patients without CMI relied significantly on the use of informational support to cope with COVID-19 disease. Patients with CMI continued to show significant depressive symptoms after 6 months without significant PTSD symptoms. COVID-19 has similar immediate psychological impact on patients with and without CMI. However, patients with CMI continue to show depression on long-term follow-up. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

22. Three regimens for re-treatment failure of Sofosbuvir-based therapy for chronic hepatitis-C genotype-4: a cohort study

Author

Shousha, Hend Ibrahim, Abdelghafour, Reem, Dabees, Hosam, Razek, Wael Abdel, and Said, Mohamed

Subjects
Adult, Male, Genotype, Hepatitis C virus, Hepacivirus, Treatment-experienced, Hepatitis C, Chronic, Middle Aged, Direct-acting antivirals, Antiviral Agents, Cohort Studies, Daclatasvir, Treatment Outcome, Ribavirin, Humans, Drug Therapy, Combination, Female, Treatment Failure, Sofosbuvir, Voxilaprevir, Ombitasvir/Paritaprevir/Ritonavir, Velpatasvir
Abstract

Despite the high sustained virologic response (SVR) rates of direct-acting antiviral (DAAs) therapy, a small number of patients does not eradicate the virus, and these patients represent a challenge. This study aims to compare the outcomes of three second-line regimens for DAAs-experienced patients with chronic hepatitis C (CHC). This prospective observational study was conducted at the Damanhur Viral Hepatitis Center from January 2017 to February 2020. We included patients with CHC who did not achieve SVR after the complete course of Sofosbuvir/Daclatasvir±Ribavirin (SOF/DAC±RBV). The primary endpoint was SVR-12 after re-treatment. This study included 360 patients (with a mean age of 51.53±11.38 years). Approximately 51.1% of the patients were males, and 65.5% had liver cirrhosis. All patients of group 1 (45 patients) received SOF/VEL/VOX over 12-weeks; SVR-12 was achieved in 44 patients (97.8%). Group 2 (28 patients) received SOF/DAC/RBV over 24-weeks; (one patient was lost during follow-ups and one patient discontinued treatment due to hepatic decompensation). SVR-12 was achieved in 25 patients (96.2%). Group 3 (287 patients) received SOF/Ombitasvir/Paritaprevir/Ritonavir/RBV) over 12-weeks. Eight patients were lost during follow-ups, and one patient discontinued treatment due to grade 4 adverse events. SVR-12 was achieved in 276 patients (99.3%). There was no difference between the groups regarding their age, gender distribution, baseline viral load or comorbidities. Adverse events (thrombocytopenia, anemia, hyperbilirubinaemia and prolonged INR) were significantly higher in group 3, while group 1 did not experience any. The three studied retreatment regimens can be used for DAAs treatment-experienced patients considering availability. The SOF/VEL/VOX combination had the least adverse events.

Published
2022

23. Assessment of circulating levels of microRNA-326, microRNA-424, and microRNA-511 as biomarkers for hepatocellular carcinoma in Egyptians

Author

Youssef, Samar Samir, primary, El fiky, Asmaa, additional, Nabeel, Mohamed M, additional, Shousha, Hend Ibrahim, additional, Elbaz, Tamer, additional, Omran, Dalia, additional, Marie, Mohammad Saeed, additional, Elzahry, Mohammad A, additional, Abul-Fotouh, Amr, additional, Hashem, Ahmed, additional, Guda, Mohamed F, additional, and Abdelaziz, Ashraf O, additional

Published
2022
Full Text
View/download PDF

26. Prediction of mortality in hospitalized Egyptian patients with Coronavirus disease-2019: A multicenter retrospective study

Author

AbdelGhaffar, Muhammad M., primary, Omran, Dalia, additional, Elgebaly, Ahmed, additional, Bahbah, Eshak I., additional, Afify, Shimaa, additional, AlSoda, Mohamed, additional, El-Shiekh, Mohamed, additional, ElSayed, Enass S., additional, Shaaban, Soha S., additional, AbdelHafez, Samah, additional, Elkelany, Khaled, additional, Eltayar, Ayman A., additional, Ali, Omnia S., additional, Kamal, Lamiaa, additional, Heiba, Ahmed M., additional, El Askary, Ahmad, additional, and Shousha, Hend Ibrahim, additional

Published
2022
Full Text
View/download PDF

29. Survival and outcomes for co-infection of chronic hepatitis C with and without cirrhosis and COVID-19: A multicenter retrospective study

Author

Afify, Shimaa, primary, Eysa, Basem, additional, Hamid, Fatma Abdel, additional, Abo-Elazm, Omnia M, additional, Edris, Mohamed A, additional, Maher, Rabab, additional, Abdelhalim, Ahmed, additional, Abdel Ghaffar, Muhammad Mostafa, additional, Omran, Dalia A, additional, and Shousha, Hend Ibrahim, additional

Published
2021
Full Text
View/download PDF

30. Hepatic and gastrointestinal disturbances in Egyptian patients infected with coronavirus disease 2019: A multicentre cohort study

Author

Shousha, Hend Ibrahim, primary, Afify, Shimaa, additional, Maher, Rabab, additional, Asem, Noha, additional, Fouad, Eman, additional, Mostafa, Ehab F, additional, Medhat, Mohammed A, additional, Abdalazeem, Amr, additional, Elmorsy, Hazem, additional, Aziz, Miriam M, additional, Mohammed, Rateba S, additional, Ibrahem, Mohamed, additional, Elgarem, Hassan, additional, Omran, Dalia, additional, Hassany, Mohamed, additional, Elsayed, Bassem, additional, Abdelaziz, Ahmed Y, additional, and El Kassas, Mohamed, additional

Published
2021
Full Text
View/download PDF

31. Anxiety, depression and coping strategies among chronic medical patients with coronavirus disease-2019: a multicenter follow-up cohort study

Author

Shousha, Hend Ibrahim, primary, Madbouly, Nagwan, additional, Afify, Shimaa, additional, Asem, Noha, additional, Fouad, Eman, additional, Maher, Rabab, additional, Moussa, Suaad Sayed, additional, Abdelazeem, Amr, additional, Youssif, Eslam Mohamed, additional, Harhira, Khalid Yousef, additional, Kamal, Kariman, additional, Elmorsy, Hazem, additional, Elgarem, Hassan, additional, Omran, Dalia, additional, Hassany, Mohamed, additional, Eysa, Basem, additional, and El Kassas, Mohamed, additional

Published
2021
Full Text
View/download PDF

32. Schistosoma mansoni infection and the occurrence, characteristics, and survival of patients with hepatocellular carcinoma: an observational study over a decade

Author

Shousha, Hend Ibrahim, primary, Abdelaziz, Ashraf Omar, additional, Nabeel, Mohamed Mahmoud, additional, Omran, Dalia Abdelhamid, additional, Abdelmaksoud, Ahmed Hosni, additional, Elbaz, Tamer Mahmoud, additional, Salah, Ayman, additional, Harb, Shady Tarek ElGhazaly, additional, Hosny, Karim Adel, additional, Osman, Ayman, additional, Atef, Mira, additional, Gaber, Abdelazez, additional, Zayed, Naglaa Ali, additional, Yosry, Ayman Abdelhady, additional, and Leithy, Rania, additional

Published
2021
Full Text
View/download PDF

39. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis

Author

Sapena, Victor, primary, Enea, Marco, additional, Torres, Ferran, additional, Celsa, Ciro, additional, Rios, Jose, additional, Rizzo, Giacomo Emanuele Maria, additional, Nahon, Pierre, additional, Mariño, Zoe, additional, Tateishi, Ryosuke, additional, Minami, Tatsuya, additional, Sangiovanni, Angelo, additional, Forns, Xavier, additional, Toyoda, Hidenori, additional, Brillanti, Stefano, additional, Conti, Fabio, additional, Degasperi, Elisabetta, additional, Yu, Ming-Lung, additional, Tsai, Pei-Chien, additional, Jean, Kevin, additional, El Kassas, Mohamed, additional, Shousha, Hend Ibrahim, additional, Omar, Ashraf, additional, Zavaglia, Claudio, additional, Nagata, Hiroko, additional, Nakagawa, Mina, additional, Asahina, Yasuhiro, additional, Singal, Amit G, additional, Murphy, Caitlin, additional, Kohla, Mohamed, additional, Masetti, Chiara, additional, Dufour, Jean-François, additional, Merchante, Nicolas, additional, Cavalletto, Luisa, additional, chemello, liliana LC, additional, POL, Stanislas, additional, Crespo, Javier, additional, Calleja, Jose Luis, additional, Villani, Rosanna, additional, Serviddio, Gaetano, additional, Zanetto, Alberto, additional, Shalaby, Sarah, additional, Russo, Francesco Paolo, additional, Bielen, Rob, additional, Trevisani, Franco, additional, Cammà, Calogero, additional, Bruix, Jordi, additional, Cabibbo, Giuseppe, additional, and Reig, Maria, additional

Published
2021
Full Text
View/download PDF

41. Psychiatric morbidities and Coping strategies in patients with different Coronavirus disease-2019 severities and chronic medical diseases: A multicenter cross-sectional study

Author

Shousha, Hend Ibrahim, primary, Madbouly, Nagwan, additional, Afify, Shaimaa, additional, Asem, Noha, additional, Maher, Rabab, additional, Moussa, Suaad Sayed, additional, Abdelazeem, Amr, additional, Youssif, Eslam Mohamed, additional, Harhira, Khalid Yousef, additional, Elmorsy, Hazem, additional, Elgarem, Hassan, additional, Omran, Dalia, additional, Hassany, Mohamed, additional, Elsayed, Bassem, additional, and El kassas, Mohamed, additional

Published
2020
Full Text
View/download PDF

42. Schistosoma mansoni infection and the occurrence, characteristics, and survival of patients with hepatocellular carcinoma: an observational study over a decade.

Author

Shousha, Hend Ibrahim, Abdelaziz, Ashraf Omar, Nabeel, Mohamed Mahmoud, Omran, Dalia Abdelhamid, Abdelmaksoud, Ahmed Hosni, Elbaz, Tamer Mahmoud, Salah, Ayman, Harb, Shady Tarek ElGhazaly, Hosny, Karim Adel, Osman, Ayman, Atef, Mira, Gaber, Abdelazez, Zayed, Naglaa Ali, Yosry, Ayman Abdelhady, and Leithy, Rania

Subjects
HEPATOCELLULAR carcinoma, HEPATITIS C virus, SCHISTOSOMIASIS, SCHISTOSOMA mansoni, ANTIVIRAL agents
Abstract

Schistosoma mansoni infection (SMI) is suspected to be directly and indirectly involved in hepato-carcinogenesis. This study evaluated the association of a previous SMI with hepatocellular carcinoma (HCC) development, patients, tumor characteristics, treatment outcomes, and survival. This observational study included patients with HCC with and without previous SMI who presented to the multidisciplinary HCC clinic, Kasr-Alainy hospital (November 2009 to December 2019). It also included 313 patients with liver cirrhosis without HCC. Clinical and laboratory features of the patients (complete blood count, liver/renal functions , alpha-fetoprotein, and hepatitis B/C status), tumor characteristics (Triphasic CT and/or dynamic MRI), liver stiffness (transient elastography), HCC treatment outcome, and overall survival were studied. This study included 1446 patients with HCC; 688(47.6%) composed group-1, defined by patients having a history of SMI, and 758(52.4%) were in group-2 and without history of SMI. Male sex, smoking, diabetes mellitus, splenomegaly, deteriorated performance status, synthetic liver functions, and platelet count were significantly higher in group-1. The groups did not differ with regard to liver stiffness, tumor characteristics, or the occurrence of post-HCC treatment hepatic decompensation or recurrence. HCC treatment response was better in group-2. Group-1 showed lower sustained virological response to hepatitis C direct-acting antivirals (DAAs) compared with group-2 (60% versus 84.3%, respectively, P = 0.027). Prior SMI was associated with HCC (adjusted odds ratio = 1.589, 95% confidence interval = 1.187–2.127), and it was concluded that it increases the risk of HCC. In addition, it significantly affects the performance status, laboratory characteristics, response to DAAs, and overall survival. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

45. Transarterial Chemoembolization Combined with Either Radiofrequency or Microwave Ablation in Management of Hepatocellular Carcinoma

Author

Abdelaziz, Ashraf Omar, Abdelmaksoud, Ahmed Hosni, Nabeel, Mohamed Mahmoud, Shousha, Hend Ibrahim, Cordie, Ahmed Abdelmonem, Mahmoud, Sherif Hamdy, Medhat, Eman, Omran, Dalia, and Elbaz, Tamer Mahmoud

Subjects
Hepatocellular carcinoma, microwave ablation, radiofrequency ablation, Research Article
Abstract

Introduction: Local ablative therapy and trans arterial chemoembolization (TACE) are applied to ablate non resectable hepatocellular carcinoma (HCC). Combination of both techniques has proven to be more effective. We aimed to study combined ablation techniques and assess survival benefit comparing TACE with radiofrequency (RFA) versus TACE with microwave (MWA) techniques. Methods: We retrospectively studied 22 patients who were ablated using TACE-RFA and 45 with TACE-MWA. All were classified as Child A-B and lesions did not exceed 5 cm in diameter. TACE was followed within two weeks by either RFA or MWA. We recorded total and partial ablation rates and complication rates. Survival analysis was then performed. Results: TACE-MWA showed a higher tendency to provide complete response rates than TACE-RFA (P 0.06). This was particularly evident with lesions sized 3-5 cm (P 0.01). Rates of complications showed no significant difference between the groups. Overall median survival was 27 months. The overall actuarial probability of survival was 80.1% at 1 year, 55% at 2 years, and 36.3% at 3 years. The recurrence free survival at 1 year, 2years and 3 years for the TACE-RFA group was 70%, 42% and 14% respectively and for TACE-MWA group 81.2%, 65.1% and 65.1% without any significant difference (P 0.1). In relation to the size of focal lesions, no statistically significant difference in the survival rates was detected between the groups. Conclusion: TACE-MWA led to better response rates than TACE-RFA with tumors 3-5 cm, with no difference in survival rates.

Published
2017

46. Portal Vein Thrombosis in Unresectable Hcc Cases: a Single Center Study of Prognostic Factors and Management in 140 Patients

Author

Abdelmaksoud, Ahmed Hosni, Mandooh, Safaa, Nabeel, Mohamed Mahmoud, Elbaz, Tamer Mahmoud, Shousha, Hend Ibrahim, Monier, Ashraf, Elattar, Inas Anwar, and Abdelaziz, Ashraf Omar

Subjects
TACE, Hepatocellular carcinoma, portal vein thrombosis, HCC prognosis, Research Article
Abstract

Objective: Hepatocellular carcinoma with portal vein thrombosis is considered a relative contraindication for transarterial chemoembolization (TACE). The aim of our study was to evaluate the prognostic factors and management in patients with hepatocellular carcinoma with portal vein thrombosis (PVT). Methods: Between February 2011 and February 2015, 140 patients presented to our specialized multidisciplinary HCC clinic. All were assessed by imaging at regular intervals for tumor response and the data compared with baseline laboratory and imaging characteristics obtained before treatment. Results: At the end of the follow up in February 2015, 78 (55.7%) of the 140 patients had died, 33.1% in the 1st year and 20.7% in the 2nd year. The overall median survival was 10 months from the date of diagnosis. Clinical progression was noted in 45 (32.1%). Univariate analysis revealed that, the Child-Pugh score, the performance states (Eastern Cooperative Oncology Group “ECOG” 0-1) and the presence of ascites exerted non-significant affects on survival. Similarly, the serum albumen level and AFP >400 ng/ml were without influence. However, patients with =>2 tumors, abdominal lymphadenopathy and serum bilirubin >2mg/dl had a significantly worse prognosis. Specific treatment significantly increased survival compared to patients left untreated (P value = 0.027). Conclusion: Application of specific treatments (curative or palliative) significantly increased survival in HCC patients with PVT. TACE can be considered as a promising procedure for unresectable PVT-associated HCCs. The main predictors of survival in our study were the serum bilirubin level and specific treatment application.

Published
2017

48. Genetic variations in death receptor domain 4 gene and the susceptibility to hepatitis C related hepatocellular carcinoma

Author

Zayed, Shahira Amin, primary, Zahran, Nariman M., additional, Khorshied, Mervat Mamdooh, additional, Abdel‐Aziz, Ashraf Omar, additional, Mahmoud, Ola, additional, Morsy, Shereif Ahmed, additional, Shousha, Hend Ibrahim, additional, Elbaz, Tamer Mahmoud, additional, Nabeel, Mohamed Mahmoud, additional, and Harb, Amira Ramadan Korany, additional

Published
2019
Full Text
View/download PDF

49. Schistosoma mansoniinfection and the occurrence, characteristics, and survival of patients with hepatocellular carcinoma: an observational study over a decade

Author

Shousha, Hend Ibrahim, Abdelaziz, Ashraf Omar, Nabeel, Mohamed Mahmoud, Omran, Dalia Abdelhamid, Abdelmaksoud, Ahmed Hosni, Elbaz, Tamer Mahmoud, Salah, Ayman, Harb, Shady Tarek ElGhazaly, Hosny, Karim Adel, Osman, Ayman, Atef, Mira, Gaber, Abdelazez, Zayed, Naglaa Ali, Yosry, Ayman Abdelhady, and Leithy, Rania

Abstract

ABSTRACTSchistosoma mansoniinfection (SMI) is suspected to be directly and indirectly involved in hepato-carcinogenesis. This study evaluated the association of a previous SMI with hepatocellular carcinoma (HCC) development, patients, tumor characteristics, treatment outcomes, and survival. This observational study included patients with HCC with and without previous SMI who presented to the multidisciplinary HCC clinic, Kasr-Alainy hospital (November 2009 to December 2019). It also included 313 patients with liver cirrhosis without HCC. Clinical and laboratory features of the patients (complete blood count, liver/renal functions , alpha-fetoprotein, and hepatitis B/C status), tumor characteristics (Triphasic CT and/or dynamic MRI), liver stiffness (transient elastography), HCC treatment outcome, and overall survival were studied. This study included 1446 patients with HCC; 688(47.6%) composed group-1, defined by patients having a history of SMI, and 758(52.4%) were in group-2 and without history of SMI. Male sex, smoking, diabetes mellitus, splenomegaly, deteriorated performance status, synthetic liver functions, and platelet count were significantly higher in group-1. The groups did not differ with regard to liver stiffness, tumor characteristics, or the occurrence of post-HCC treatment hepatic decompensation or recurrence. HCC treatment response was better in group-2. Group-1 showed lower sustained virological response to hepatitis C direct-acting antivirals (DAAs) compared with group-2 (60% versus 84.3%, respectively, P = 0.027). Prior SMI was associated with HCC (adjusted odds ratio = 1.589, 95% confidence interval = 1.187–2.127), and it was concluded that it increases the risk of HCC. In addition, it significantly affects the performance status, laboratory characteristics, response to DAAs, and overall survival.

Published
2022
Full Text
View/download PDF

50. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis

Author

Sapena, Victor, Enea, Marco, Torres, Ferran, Celsa, Ciro, Rios, Jose, Rizzo, Giacomo Emanuele Maria, Nahon, Pierre, Mariño, Zoe, Tateishi, Ryosuke, Minami, Tatsuya, Sangiovanni, Angelo, Forns, Xavier, Toyoda, Hidenori, Brillanti, Stefano, Conti, Fabio, Degasperi, Elisabetta, Yu, Ming-Lung, Tsai, Pei-Chien, Jean, Kevin, El Kassas, Mohamed, Shousha, Hend Ibrahim, Omar, Ashraf, Zavaglia, Claudio, Nagata, Hiroko, Nakagawa, Mina, Asahina, Yasuhiro, Singal, Amit G, Murphy, Caitlin, Kohla, Mohamed, Masetti, Chiara, Dufour, Jean-Francois, Merchante, Nicolas, Cavalletto, Luisa, chemello, liliana LC, POL, Stanislas, Crespo, Javier, Calleja, Jose Luis, Villani, Rosanna, Serviddio, Gaetano, Zanetto, Alberto, Shalaby, Sarah, Russo, Francesco Paolo, Bielen, Rob, Trevisani, Franco, Cammà, Calogero, Bruix, Jordi, Cabibbo, Giuseppe, and Reig, Maria

Abstract

ObjectiveThe benefit of direct-acting antivirals (DAAs) against HCV following successful treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of individual patient data assessed HCC recurrence risk following DAA administration.DesignWe pooled the data of 977 consecutive patients from 21 studies of HCV-related cirrhosis and HCC, who achieved complete radiological response after surgical/locoregional treatments and received DAAs (DAA group). Recurrence or death risk was expressed as HCC recurrence or death per 100 person-years (100PY). Propensity score-matched patients from the ITA.LI.CA. cohort (n=328) served as DAA-unexposed controls (no-DAA group). Risk factors for HCC recurrence were identified using random-effects Poisson.ResultsRecurrence rate and death risk per 100PY in DAA-treated patients were 20 (95% CI 13.9 to 29.8, I2=74.6%) and 5.7 (2.5 to 15.3, I2=54.3), respectively. Predictive factors for recurrence were alpha-fetoprotein logarithm (relative risk (RR)=1.11, 95% CI 1.03 to 1.19; p=0.01, per 1 log of ng/mL), HCC recurrence history pre-DAA initiation (RR=1.11, 95% CI 1.07 to 1.16; p<0.001), performance status (2 vs 0, RR=4.35, 95% CI 1.54 to 11.11; 2 vs 1, RR=3.7, 95% CI 1.3 to 11.11; p=0.01) and tumour burden pre-HCC treatment (multifocal vs solitary nodule, RR=1.75, 95% CI 1.25 to 2.43; p<0.001). No significant difference was observed in RR between the DAA-exposed and DAA-unexposed groups in propensity score-matched patients (RR=0.64, 95% CI 0.37 to 1.1; p=0.1).ConclusionEffects of DAA exposure on HCC recurrence risk remain inconclusive. Active clinical and radiological follow-up of patients with HCC after HCV eradication with DAA is justified.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results